0000899243-19-007818.txt : 20190314 0000899243-19-007818.hdr.sgml : 20190314 20190314212523 ACCESSION NUMBER: 0000899243-19-007818 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20190313 FILED AS OF DATE: 20190314 DATE AS OF CHANGE: 20190314 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Ragan Paula CENTRAL INDEX KEY: 0001769914 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38295 FILM NUMBER: 19682702 MAIL ADDRESS: STREET 1: C/O X4 PHARMACEUTICALS, INC. STREET 2: 955 MASSACHUSETTS AVE., 4TH FLOOR CITY: CAMBRIDGE STATE: MA ZIP: 02139 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: X4 Pharmaceuticals, Inc CENTRAL INDEX KEY: 0001501697 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 273181608 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 955 MASSACHUSETTS AVENUE STREET 2: 4TH FLOOR CITY: CAMBRIDGE STATE: MA ZIP: 02139 BUSINESS PHONE: 857-529-8300 MAIL ADDRESS: STREET 1: 955 MASSACHUSETTS AVENUE STREET 2: 4TH FLOOR CITY: CAMBRIDGE STATE: MA ZIP: 02139 FORMER COMPANY: FORMER CONFORMED NAME: Arsanis, Inc. DATE OF NAME CHANGE: 20100920 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2019-03-13 0 0001501697 X4 Pharmaceuticals, Inc XFOR 0001769914 Ragan Paula C/O X4 PHARMACEUTICALS, INC. 955 MASSACHUSETTS AVENUE, 4TH FLOOR CAMBRIDGE MA 02139 1 1 0 0 President and CEO Common Stock 2019-03-13 4 A 0 181366 A 181366 D Stock Option (right to buy) 6.84 2019-03-13 4 A 0 100729 A 2026-01-18 Common Stock 100729 100729 D Stock Option (right to buy) 6.84 2019-03-13 4 A 0 65430 A 2027-01-23 Common Stock 65430 65430 D Stock Option (right to buy) 7.08 2019-03-13 4 A 0 80160 A 2028-01-30 Common Stock 80160 80160 D Received in exchange for 1,870,000 shares of common stock of X4 Therapeutics, Inc. (formerly X4 Pharmaceuticals, Inc.) ("X4") and 38,451 shares of Series Seed preferred stock of X4 in connection with the merger of Artemis AC Corp., a wholly-owned subsidiary of the Issuer, with and into X4 (the "Merger") on March 13, 2019. Fully vested. Reflects the Reporting Person's stock option to acquire 1,059,935 shares of X4 common stock for $0.65 per share that was assumed by the Issuer in the Merger. Twenty-five percent (25%) of the shares subject to the option vested on January 24, 2018, and one thirty-sixth (1/36th) of the remaining shares subject to the option shall vest each month thereafter, subject to the Reporting Person continuing to provide service through each such date. Reflects the Reporting Person's stock option to acquire 688,500 shares of X4 common stock for $0.65 per share that was assumed by the Issuer in the Merger. Twenty-five percent (25%) of the shares subject to the option vested on January 31, 2019, and one thirty-sixth (1/36th) of the remaining shares subject to the option shall vest each month thereafter, subject to the Reporting Person continuing to provide service through each such date. Reflects the Reporting Person's stock option to acquire 843,496 shares of X4 common stock for $0.67 per share that was assumed by the Issuer in the Merger. All share and per share amounts of the Issuer's common stock and stock options reported in this Form 4 reflect the 1-for-6 reverse stock split of the Issuer's common stock effected on March 13, 2019 after the completion of the Merger. /s/ Adam S. Mostafa, attorney-in-fact 2019-03-14